Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $640.00 Price Target at BMO Capital Markets

Key Points

• BMO Capital Markets has increased its price target for Regeneron Pharmaceuticals' stock from $600 to $640, suggesting a potential upside of 12.75% from the previous closing price.
• Regeneron reported earnings of $12.89 per share, surpassing analysts' expectations of $8.43, with revenue of $3.68 billion for the quarter, reflecting a year-over-year growth of 3.6%.
• The consensus rating for Regeneron Pharmaceuticals currently stands at "Moderate Buy", with an average target price of $841.30 based on various analysts’ assessments.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) had its target price hoisted by equities researchers at BMO Capital Markets from $600.00 to $640.00 in a report released on Monday,Benzinga reports. The brokerage currently has an "outperform" rating on the biopharmaceutical company's stock. BMO Capital Markets' price objective suggests a potential upside of 12.75% from the stock's previous close.

Other equities research analysts have also recently issued reports about the stock. Canaccord Genuity Group reissued a "buy" rating and issued a $850.00 price target on shares of Regeneron Pharmaceuticals in a research report on Wednesday, July 23rd. JPMorgan Chase & Co. reduced their target price on Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating for the company in a report on Monday, June 9th. Royal Bank Of Canada raised their price target on Regeneron Pharmaceuticals from $688.00 to $695.00 and gave the stock a "sector perform" rating in a research note on Monday. Guggenheim boosted their price objective on Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the company a "buy" rating in a research note on Friday. Finally, Bank of America lowered their target price on shares of Regeneron Pharmaceuticals from $575.00 to $547.00 and set an "underperform" rating on the stock in a research report on Thursday, April 17th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, sixteen have issued a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $841.30.

Regeneron Pharmaceuticals Stock Up 1.6%

Shares of NASDAQ:REGN traded up $8.75 during trading on Monday, hitting $567.62. The company's stock had a trading volume of 580,957 shares, compared to its average volume of 1,116,136. Regeneron Pharmaceuticals has a fifty-two week low of $476.49 and a fifty-two week high of $1,211.20. The business has a 50 day moving average price of $538.05 and a two-hundred day moving average price of $602.76. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.73 and a current ratio of 5.39. The company has a market capitalization of $61.28 billion, a PE ratio of 14.31, a P/E/G ratio of 2.10 and a beta of 0.33.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings data on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, beating analysts' consensus estimates of $8.43 by $4.46. The business had revenue of $3,675,600 billion for the quarter, compared to analyst estimates of $3.30 billion. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The company's revenue was up 3.6% on a year-over-year basis. During the same period last year, the business earned $11.56 EPS. As a group, research analysts expect that Regeneron Pharmaceuticals will post 35.92 EPS for the current fiscal year.

Institutional Trading of Regeneron Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 1.3% during the 1st quarter. Vanguard Group Inc. now owns 9,407,891 shares of the biopharmaceutical company's stock worth $5,966,767,000 after purchasing an additional 121,545 shares during the last quarter. Capital International Investors raised its holdings in Regeneron Pharmaceuticals by 41.6% in the 4th quarter. Capital International Investors now owns 4,736,929 shares of the biopharmaceutical company's stock valued at $3,373,859,000 after acquiring an additional 1,390,534 shares during the last quarter. Dodge & Cox lifted its stake in shares of Regeneron Pharmaceuticals by 0.4% during the 4th quarter. Dodge & Cox now owns 2,321,316 shares of the biopharmaceutical company's stock worth $1,653,543,000 after purchasing an additional 9,381 shares during the period. Price T Rowe Associates Inc. MD boosted its holdings in shares of Regeneron Pharmaceuticals by 4.3% during the first quarter. Price T Rowe Associates Inc. MD now owns 2,175,026 shares of the biopharmaceutical company's stock worth $1,379,467,000 after purchasing an additional 89,579 shares during the last quarter. Finally, Amundi grew its position in shares of Regeneron Pharmaceuticals by 3.4% in the first quarter. Amundi now owns 1,603,901 shares of the biopharmaceutical company's stock valued at $979,794,000 after purchasing an additional 52,166 shares during the period. Hedge funds and other institutional investors own 83.31% of the company's stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.